This story originally ran on Feb. 1.

Thermo Fisher Scientific this week reported $3.13 billion in Q4 2011 revenues, up 15 percent from $2.72 billion in Q4 2010 and beating Wall Street estimates of $3.08 billion.

On a conference call to discuss the financial results, president and CEO Marc Casper highlighted the launch of new products, including the Q Exactive mass spectrometer, as a "key aspect" of the company's revenue growth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.